Methylation of miR-378 in Chronic Myeloid Leukemia.

De-hong WU; Jing Yang; Lei Yang; Xiang-mei Wen; Hong Guo; Dong-ming Yao; Jiang Lin; Ying-ying Zhang; Ming Zhang; Zhao-qun Deng; Jun Qian

Return

Methylation of miR-378 in Chronic Myeloid Leukemia.

Author: De-Hong WU ¹ ; Jing YANG ¹ ; Lei YANG ¹ ; Xiang-Mei WEN ² ; Hong GUO ² ; Dong-Ming YAO ³ ; Jiang LIN ² ; Ying-Ying ZHANG ¹ ; Ming ZHANG ² ; Zhao-Qun DENG ² ; Jun QIAN ⁴
Author Information

1. Department of Hematology, The First Affiliated Hospital of Jiangsu University, Zhengjiang 212002, Jiangsu Province, China.
2. Central Laboratory, The First Affiliated Hospital of Jiangsu University, Zhengjiang 212002, Jiangsu Province, China.
3. Department of Clinical Laboratorial Examination, The First Affiliated Hospital of Jiangsu University, Zhengjiang 212002, Jiangsu Province, China.
4. Department of Hematology, The First Affiliated Hospital of Jiangsu University, Zhengjiang 212002, Jiangsu Province, China. E-mail: qianjun0007@sina.com.
Publication Type:Journal Article
MeSH: Bone Marrow Cells; metabolism; Case-Control Studies; DNA Methylation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; genetics; MicroRNAs; metabolism; Promoter Regions, Genetic
From: Journal of Experimental Hematology 2016;24(1):61-65
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the methylation status of miR-378 promoter in chronic myeloid leukemia (CML) and to analyze its clinical significance.
METHODSThe unmethylation level of miR-378 gene promoter in bone marrow mononuclear cells of 25 healthy donors and 53 patients with CML was detected by using real-time quantitative methylation-specific PCR (RQ-MSP).
RESULTSThe hypomethylation of miR-378 gene promoter was found in 17/53 (32.1%) patients, but only in 1/25 (4.0%) of controls. The difference between the two groups was very statistically significant (P < 0.01). The frequency of miR-378 unmethylation in CML patients at chronic phase (CP), accelerated phase (AP) and blastic phase (BP) was 35.0% (14/40), 40.0% (2/5), and 12.5% (1/8), respectively. However, there were no significant differences in the unmethylation level of miR-378 among CML patients at different sexes, stages and karyotypes. No significant differences could be observed in age, white blood cell counts, platelet count, hemoglobin level and BCR/ABL1 transcript level (P > 0.05). CONCLUDSION: The miR-378 hypomethylation is a common molecular event in CML, especially at chronic or accelerated phases.